Zhu R, Chen TZ, Sun MT, Zhu CR. Advanced cervix cancer patient with chemotherapy-induced grade IV myelosuppression achieved complete remission with cadonilimab: A case report. World J Clin Cases 2024; 12(8): 1510-1516 [PMID: 38576806 DOI: 10.12998/wjcc.v12.i8.1510]
Corresponding Author of This Article
Chun-Rong Zhu, DPhil, PhD, Associate Professor, Chief Doctor, Department of Oncology, The First Affiliated Hospital of Soochow University, No. 188 Shizi Street, Gusu District, Suzhou 215000, Jiangsu Province, China. zcr050311@163.com
Research Domain of This Article
Oncology
Article-Type of This Article
Case Report
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
Zhu R, Chen TZ, Sun MT, Zhu CR. Advanced cervix cancer patient with chemotherapy-induced grade IV myelosuppression achieved complete remission with cadonilimab: A case report. World J Clin Cases 2024; 12(8): 1510-1516 [PMID: 38576806 DOI: 10.12998/wjcc.v12.i8.1510]
Rui Zhu, Meng-Ting Sun, Chun-Rong Zhu, Department of Oncology, The First Affiliated Hospital of Soochow University, Suzhou 215000, Jiangsu Province, China
Tian-Ze Chen, Department of Urology, The First Affiliated Hospital of Soochow University, Suzhou 215000, Jiangsu Province, China
Author contributions: Zhu R and Chen TZ contributed to manuscript writing and editing, and data collection; Sun MT contributed to data analysis; Zhu CR contributed to conceptualization and supervision; all authors have read and approved the final manuscript.
Informed consent statement: Informed written consent was obtained from the patient for publication of this report and any accompanying images.
Conflict-of-interest statement: The authors declare that they have no conflict of interest to disclose.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Chun-Rong Zhu, DPhil, PhD, Associate Professor, Chief Doctor, Department of Oncology, The First Affiliated Hospital of Soochow University, No. 188 Shizi Street, Gusu District, Suzhou 215000, Jiangsu Province, China. zcr050311@163.com
Received: December 12, 2023 Peer-review started: December 12, 2023 First decision: January 9, 2024 Revised: January 18, 2024 Accepted: February 22, 2024 Article in press: February 22, 2024 Published online: March 16, 2024 Processing time: 90 Days and 15.4 Hours
Abstract
BACKGROUND
The prognosis for patients with advanced metastatic cervix cancer (MCC) is poor, and this disease continues to pose a considerable therapeutic challenge. Despite the administration of first-line regimens consisting of cisplatin, paclitaxel, and bevacizumab, survival rates for patients with metastasis remain poor. The emergence of bispecific antibodies (BsAbs) offers a novel treatment option for patients diagnosed with MCC.
CASE SUMMARY
In this report, we present a patient with MCC who was treated with cadonilimab monotherapy at a dose of 6 mg/kg every two weeks after chemotherapy was proven to be intolerable. The patient exhibited a sustained complete response for a duration of 6 months, demonstrating an optimistic outlook.
CONCLUSION
This case illustrates the considerable efficacy of cadonilimab for treating advanced MCC. Therefore, BsAb therapy is a promising strategy for effectively treating patients with advanced MCC and should be considered as an option when patients are intolerant to standard chemotherapy.
Core Tip: Advanced metastatic cervical cancer (MCC) has a poor prognosis and a low survival rate. The emergence of bispecific antibodies offers a novel treatment option for patients with MCC. Cadonilimab is a tetravalent bispecific antibody designed to simultaneously block the programmed death protein 1 (PD-1) and cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) pathways while substantially reducing toxicities compared to combination therapy with PD-1 and CTLA-4 antibodies. We report the case of a patient with advanced MCC who achieved a complete response with cadonilimab monotherapy despite chemotherapy-induced grade IV myelosuppression.
